Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.6K Buy
3,829
+105
+3% +$872 ﹤0.01% 2685
2025
Q4
$38.8K Sell
3,724
-112
-3% -$1.12K ﹤0.01% 2335
2025
Q3
$34.5K Buy
3,836
+4
+0.1% +$35 ﹤0.01% 2272
2025
Q2
$49.8K Buy
3,832
+133
+4% +$2K ﹤0.01% 2056
2025
Q1
$93.5K Sell
3,699
-2
-0.1% -$59 ﹤0.01% 1566
2024
Q4
$127K Buy
3,701
+1
+0% +$45 ﹤0.01% 1346
2024
Q3
$183K Hold
3,700
0.01% 1137
2024
Q2
$223K Hold
3,700
0.01% 992
2024
Q1
$191K Hold
3,700
0.01% 1022
2023
Q4
$149K Sell
3,700
-382
-9% -$11.2K 0.01% 1094
2023
Q3
$114K Buy
4,082
+200
+5% +$5.96K 0.01% 1195
2023
Q2
$112K Buy
+3,882
New +$86.4K ﹤0.01% 1267

Other funds holding RXST

IFP Advisors's RXST Position: Q1 2026 in Review

IFP Advisors increased its RxSight (RXST) stake by 2.8% in Q1 2026, buying an estimated $872 and bringing the position to 3,829 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

IFP Advisors first reported a position in RXST in Q2 2023 and has held it in 12 quarters since. The position peaked at $223K in Q2 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • IFP Advisors held 3,829 shares of RxSight worth $23.6K as of Q1 2026.
  • IFP Advisors bought 105 RxSight shares in Q1 2026, an estimated $872.
  • RxSight made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #2685 holding.
  • IFP Advisors first reported a position in RxSight in Q2 2023 and has held it in 12 quarters since.
  • IFP Advisors's RxSight position peaked at $223K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.